TTrialPathMatch Me to Trials
← Back to trials
RecruitingAlzheimer DiseaseFrontotemporal DementiaDementia

First-in-Human Evaluation of an Astrocytic Glutamate Transporter (EAAT2) PET Tracer in Dementia

Eligible age

40–75 yrs

Accepts

All genders

Locations

1 state

Healthy volunteers

Yes

See if you qualify for this study

Answer a few quick questions about your location and health. Takes about a minute.

Check my eligibility →

About this study

This is a first in human study that will assess the safety and diagnostic performance of \[18F\]RP-115 (fluorine-18 labeled RP115), a positron emission tomography (PET) agent. This agent has the potential to identify the early changes that occur in the brains of patients with Alzheimer's disease (AD) and frontotemporal dementia (FTD).

Sponsor: David Wilson

You may qualify if…

  • ✓ 1. Age 40-75
  • ✓ 2. Age-suitable BMI
  • ✓ 3. Ability to provide written informed consent and willingly comply with protocol requirements or has a legal authorized representative/guardian who provides surrogate informed consent.
  • ✓ 4. No apparent physical disorder.
  • ✓ 5. Radial, ulnar, or brachial artery suitable for catheterization.
  • ✓ 6. Non-smoker, and not taking OTC nicotine cessation - to limit peripheral metabolism events.
  • ✓ 7. Devoid of CNS prescription drugs for three weeks - to limit peripheral metabolism events.
  • ✓ For Cohort 2B and 2C:

You may not qualify if…

  • ✕ 1. Unable to provide written informed consent and unwilling to comply with protocol requirements, or does not have a legal authorized representative/guardian who can provide surrogate informed consent.
  • ✕ 2. Inadequate arterial access.
  • ✕ 3. Receipt of radioisotope \< 5 half-lives within \[18F\]RP-115 imaging- as to not confound any scans with radiation background for previous scanning, and unsuitable organ dosimetry thresholds from previous (\> two weeks) PET scans.
  • ✕ 4. The performed \[18F\]RP-115 scan(s) must not represent \> 3 PET studies total within one year.
  • ✕ 5. Contra-indication to magnetic resonance, including permanent pacemaker, implantable metallic device, etc.; or severe claustrophobia.
  • ✕ 6. Participants who are pregnant (female patients of childbearing age will be tested prior to injection of tracer- positive test excludes from the study)
  • ✕ 7. Participants who are breast-feeding.
  • ✕ 8. Have a medical condition or other circumstances that in the opinion of the project physicians would significantly decrease chances of obtaining reliable data, achieving the study objective or completing the study.

Where it's recruiting

California

San Francisco

Source: ClinicalTrials.gov · NCT05374278 · last updated 2025-04-17

First-in-Human Evaluation of an Astrocytic Glutamate Transporter (EAAT · TrialPath